EFNA3

Summary

EFNA3 (ephrin A3, HGNC:3223) is a protein-coding gene on chromosome 1q21.3, encoding Ephrin-A3 (P52797). Cell surface GPI-bound ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development.

This gene encodes a member of the ephrin (EPH) family. The ephrins and EPH-related receptors comprise the largest subfamily of receptor protein-tyrosine kinases and have been implicated in mediating developmental events, especially in the nervous system and in erythropoiesis. Based on their structures and sequence relationships, ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins. This gene encodes an EFNA class ephrin.

Source: NCBI Gene 1944 — RefSeq curated summary.

At a glance

• GWAS associations: 21
• Clinical variants (ClinVar): 32 total
• MANE Select transcript: NM_004952

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3223
Approved symbol	EFNA3
Name	ephrin A3
Location	1q21.3
Locus type	gene with protein product
Status	Approved
Aliases	LERK3, Ehk1-L
Ensembl gene	ENSG00000143590
Ensembl biotype	protein_coding
OMIM	601381
Entrez	1944

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000368408, ENST00000470294, ENST00000498667, ENST00000865007, ENST00000922316

RefSeq mRNA: 1 — MANE Select: NM_004952 NM_004952

CCDS: CCDS1090

Canonical transcript exons

ENST00000368408 — 5 exons

Exon	Start	End
ENSE00001447060	155078837	155079069
ENSE00001956523	155086413	155087538
ENSE00003551944	155085091	155085404
ENSE00003628618	155086128	155086205
ENSE00003659952	155085877	155085942

Expression profiles

Bgee: expression breadth ubiquitous, 217 present calls, max score 96.12.

FANTOM5 (CAGE): breadth broad, TPM avg 2.4385 / max 126.2471, expressed in 606 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
5567	2.2318	590
5568	0.2067	120

Top tissues by expression

271 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of leg	UBERON:0001511	96.12	gold quality
skin of abdomen	UBERON:0001416	95.69	gold quality
upper arm skin	UBERON:0004263	94.86	silver quality
lower esophagus mucosa	UBERON:0035834	94.30	gold quality
zone of skin	UBERON:0000014	93.97	gold quality
tongue squamous epithelium	UBERON:0006919	93.60	silver quality
hair follicle	UBERON:0002073	92.06	silver quality
cortical plate	UBERON:0005343	91.13	gold quality
CA1 field of hippocampus	UBERON:0003881	90.16	silver quality
diaphragm	UBERON:0001103	89.05	gold quality
cervix epithelium	UBERON:0004801	88.53	silver quality
orbitofrontal cortex	UBERON:0004167	88.23	gold quality
cervix squamous epithelium	UBERON:0006922	88.08	silver quality
prefrontal cortex	UBERON:0000451	88.04	gold quality
esophagus mucosa	UBERON:0002469	87.39	gold quality
parotid gland	UBERON:0001831	87.14	silver quality
nucleus accumbens	UBERON:0001882	86.93	gold quality
Brodmann (1909) area 9	UBERON:0013540	86.60	gold quality
Brodmann (1909) area 46	UBERON:0006483	86.29	gold quality
right frontal lobe	UBERON:0002810	86.21	gold quality
frontal cortex	UBERON:0001870	86.10	gold quality
lateral nuclear group of thalamus	UBERON:0002736	86.03	silver quality
neocortex	UBERON:0001950	85.54	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	85.25	gold quality
gingival epithelium	UBERON:0001949	85.20	silver quality
cingulate cortex	UBERON:0003027	84.94	gold quality
anterior cingulate cortex	UBERON:0009835	84.92	gold quality
putamen	UBERON:0001874	84.69	gold quality
gingiva	UBERON:0001828	84.61	gold quality
triceps brachii	UBERON:0001509	84.52	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.90

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): DICER1

miRNA regulators (miRDB)

79 targeting EFNA3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-1287-3P	99.63	66.93	492
HSA-MIR-762	99.58	66.61	1994

Literature-anchored findings (GeneRIF, showing 17)

• EphA2/ephrin-A3 interactions may play a role in the localization and network of Langerhans cells in the epithelium and in the regulation of their trafficking. (PMID:12907451)
• analysis of molecular surfaces in ephrin-A5 essential for a functional interaction with EphA3 (PMID:15901737)
• Increasing ephrin-A expression enhances T-cell interactions not only with purified integrin ligands but also endothelial cells, while EphA activation down-regulates these interactions. (PMID:17980912)
• MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. (PMID:18417479)
• EphA3 mutants with constitutively-released kinase domains efficiently support shedding, even when their kinase is disabled. Our data suggest that this phosphorylation-activated conformational switch of EphA3 directly controls ADAM-mediated shedding. (PMID:19823572)
• The interaction between ephrin-As, Eph receptors and integrin alpha3 is plausibly important for the crosstalk between Eph and integrin signalling pathways at the membrane protrusions and in the migration of brain cancer cells. (PMID:23686814)
• The present study provides evidence that microglia upregulates endothelial ephrin-A3 and ephrin-A4 to facilitate in vitro angiogenesis of brain endothelial cells, which is mediated by microglia-released TNF-alpha. (PMID:25070915)
• Results show that EFNA3 serves as a tumor suppressor in malignant peripheral nerve sheath tumor cells and it may play a critical role in the FAK signaling and VEGF-associated tumor angiogenesis pathway. (PMID:25955218)
• E2F3 and ephrin A3 are putative targets of miR-210, and their protein expression was up-regulated in the angiosarcoma cells (PMID:28739548)
• MiR-210-3p-EphrinA3-PI3K/AKT axis regulates the progression of oral cancer. (PMID:32180353)
• OSCC Exosomes Regulate miR-210-3p Targeting EFNA3 to Promote Oral Cancer Angiogenesis through the PI3K/AKT Pathway. (PMID:32695810)
• Role of EphrinA3 in HIV-1 Neuropathogenesis. (PMID:34618621)
• Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma. (PMID:35227773)
• LncRNA LINC01270 aggravates the progression of gastric cancer through modulation of miR-326/EFNA3 axis. (PMID:35345980)
• EphrinA3 is a key regulator of malignant behaviors and a potential prognostic factor in lung adenocarcinoma. (PMID:35770949)
• Small extracellular vesicles derived from hypoxic mesenchymal stem cells promote vascularized bone regeneration through the miR-210-3p/EFNA3/PI3K pathway. (PMID:35850484)
• Hsa_circ_0007478 aggravates NLRP3 inflammasome activation and lipid metabolism imbalance in ox-LDL-stimulated macrophage via miR-765/EFNA3 axis. (PMID:36191606)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	efna3b	ENSDARG00000098295
mus_musculus	Efna3	ENSMUSG00000028039
rattus_norvegicus	Efna3	ENSRNOG00000057322
drosophila_melanogaster	Ephrin	FBGN0040324
caenorhabditis_elegans		WBGENE00001163
caenorhabditis_elegans		WBGENE00001164
caenorhabditis_elegans		WBGENE00001165
caenorhabditis_elegans		WBGENE00006869

Paralogs (7): EFNB1 (ENSG00000090776), EFNA2 (ENSG00000099617), EFNB3 (ENSG00000108947), EFNB2 (ENSG00000125266), EFNA1 (ENSG00000169242), EFNA5 (ENSG00000184349), EFNA4 (ENSG00000243364)

Protein

Protein identifiers

Ephrin-A3 — P52797 (reviewed: P52797)

Alternative names: EFL-2, EHK1 ligand, EPH-related receptor tyrosine kinase ligand 3

All UniProt accessions (1): P52797

UniProt curated annotations — full annotation on UniProt →

Function. Cell surface GPI-bound ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling.

Subunit / interactions. Interacts with EPHA8; activates EPHA8.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in brain, skeletal muscle, spleen, thymus, prostate, testis, ovary, small intestine, and peripheral blood leukocytes.

Similarity. Belongs to the ephrin family.

Isoforms (2)

UniProt ID	Names	Canonical?
P52797-1	1	yes
P52797-2	2

RefSeq proteins (1): NP_004943* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001799	Ephrin_RBD	Domain
IPR008972	Cupredoxin	Homologous_superfamily
IPR019765	Ephrin_CS	Conserved_site
IPR031328	Ephrin	Family
IPR034252	Ephrin-A_Ecto	Domain

Pfam: PF00812

UniProt features (13 total): glycosylation site 3, disulfide bond 2, signal peptide 1, chain 1, splice variant 1, sequence variant 1, sequence conflict 1, propeptide 1, domain 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P52797-F1	74.84	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 214

Disulfide bonds (2): 63–110, 99–158

Glycosylation sites (3): 38, 67, 100

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-2682334	EPH-Ephrin signaling
R-HSA-3928663	EPHA-mediated growth cone collapse
R-HSA-3928665	EPH-ephrin mediated repulsion of cells

MSigDB gene sets: 222 (showing top): BENPORATH_ES_WITH_H3K27ME3, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, RORA1_01, PEREZ_TP63_TARGETS, LFA1_Q6, MODULE_64, HOEGERKORP_CD44_TARGETS_TEMPORAL_DN, GOBP_NEUROGENESIS, CTATGCA_MIR153, GOBP_CELL_CELL_SIGNALING, GCM_PRKCG, VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_UP, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_REGULATION_OF_AMYLOID_PRECURSOR_PROTEIN_CATABOLIC_PROCESS, NFKB_C

GO Biological Process (5): cell-cell signaling (GO:0007267), axon guidance (GO:0007411), negative regulation of angiogenesis (GO:0016525), ephrin receptor signaling pathway (GO:0048013), positive regulation of amyloid precursor protein catabolic process (GO:1902993)

GO Molecular Function (3): transmembrane-ephrin receptor activity (GO:0005005), ephrin receptor binding (GO:0046875), protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), side of membrane (GO:0098552), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
EPH-Ephrin signaling	2
Axon guidance	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
membrane	2
cellular anatomical structure	2
cell communication	1
signaling	1
axonogenesis	1
neuron projection guidance	1
angiogenesis	1
regulation of angiogenesis	1
negative regulation of blood vessel morphogenesis	1
cell surface receptor protein tyrosine kinase signaling pathway	1
amyloid precursor protein catabolic process	1
positive regulation of protein metabolic process	1
regulation of amyloid precursor protein catabolic process	1
ephrin receptor activity	1
signaling receptor binding	1
binding	1
cell periphery	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

888 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EFNA3	EPHA4	P54764	999
EFNA3	EPHA1	P21709	997
EFNA3	EPHA2	P29317	993
EFNA3	EPHA10	Q5JZY3	960
EFNA3	EPHA5	P54756	954
EFNA3	EPHA3	P29320	939
EFNA3	EPHA7	Q15375	909
EFNA3	EPHA8	P29322	857
EFNA3	EPHB2	P29323	832
EFNA3	EPHB6	O15197	798
EFNA3	NGEF	Q8N5V2	749
EFNA3	EPHB1	P54762	747
EFNA3	EPHB3	P54753	735
EFNA3	EPHB4	P54760	708
EFNA3	FN1	P02751	681

IntAct

28 interactions, top by confidence:

A	B	Type	Score
EFNA3	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
EFNA3		psi-mi:“MI:0915”(physical association)	0.560
EFNA3	NOTCH2NLA	psi-mi:“MI:0915”(physical association)	0.560
MEOX2	EFNA3	psi-mi:“MI:0915”(physical association)	0.560
	EFNA3	psi-mi:“MI:0915”(physical association)	0.560
EFNA3	KRTAP1-1	psi-mi:“MI:0915”(physical association)	0.560
EFNA3	LCE2C	psi-mi:“MI:0915”(physical association)	0.560
AKT1	EFNA3	psi-mi:“MI:2364”(proximity)	0.470
AKT1	EFNA3	psi-mi:“MI:0915”(physical association)	0.470
	EFNA3	psi-mi:“MI:0407”(direct interaction)	0.440
INSR	BLTP3B	psi-mi:“MI:0914”(association)	0.350
SPOP	EFNA3	psi-mi:“MI:2364”(proximity)	0.270
EFNA3	SPOP	psi-mi:“MI:2364”(proximity)	0.270
EFNA3	EGFR	psi-mi:“MI:2364”(proximity)	0.270
BRAF	EFNA3	psi-mi:“MI:2364”(proximity)	0.270
EFNA3	KRTAP1-1	psi-mi:“MI:0915”(physical association)	0.000
EFNA3	LCE2C	psi-mi:“MI:0915”(physical association)	0.000
PRSS23	EFNA3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (119): MEOX2 (Two-hybrid), KRTAP10-3 (Two-hybrid), NOTCH2NL (Two-hybrid), EFNA3 (Two-hybrid), LCE2C (Two-hybrid), KRTAP1-1 (Two-hybrid), EPHA7 (Affinity Capture-Western), EFNA3 (Reconstituted Complex), KRT1 (Affinity Capture-MS), SUMF2 (Affinity Capture-MS), EPHA2 (Affinity Capture-MS), KRT2 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), KRT10 (Affinity Capture-MS), KRT6B (Affinity Capture-MS)

ESM2 similar proteins: A5A8Y8, A7MBM2, E9PY61, O08542, O08545, O08717, O43921, O75888, O77805, O77835, P04087, P05111, P07434, P07994, P17490, P34820, P43031, P52794, P52797, P52798, P52801, P55101, P58166, Q16586, Q24JP5, Q28686, Q5Q0T9, Q5RJL6, Q5SZI1, Q641Q3, Q6PGN1, Q6PRD1, Q6ZVN8, Q7TQ32, Q7Z5Y6, Q80WF4, Q8C1Q4, Q8K1S7, Q8N7M5, Q8NCW0

Diamond homologs: O08542, O08543, O08545, O35393, O43921, O73612, O73874, P20827, P52793, P52794, P52795, P52796, P52797, P52798, P52799, P52800, P52801, P52802, P52803, P52804, P79727, P79728, P97553, P97605, P98172, Q06AS9, Q15768, Q3ZC64, O13097, O44516

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
EFNA3	up-regulates	EPHA2	binding
EFNA3	up-regulates	EPHA3	binding
EFNA3	up-regulates	EPHA4	binding
EFNA3	up-regulates	EPHA5	binding
EFNA3	up-regulates	EPHA7	binding
EFNA3	up-regulates	EPHA8	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

32 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	27
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

902 predictions. Top by Δscore:

Variant	Effect	Δscore
1:155079065:CAGCA:C	donor_gain	1.0000
1:155079066:AGCA:A	donor_gain	1.0000
1:155079067:GCA:G	donor_gain	1.0000
1:155079067:GCAG:G	donor_gain	1.0000
1:155079068:CA:C	donor_gain	1.0000
1:155079070:G:GG	donor_gain	1.0000
1:155079070:G:T	donor_loss	1.0000
1:155079071:T:G	donor_loss	1.0000
1:155085089:A:AG	acceptor_gain	1.0000
1:155085090:G:GG	acceptor_gain	1.0000
1:155085400:CATCT:C	donor_gain	1.0000
1:155085401:ATCT:A	donor_gain	1.0000
1:155085402:TCT:T	donor_gain	1.0000
1:155085403:CT:C	donor_gain	1.0000
1:155085404:TGT:T	donor_loss	1.0000
1:155085405:G:C	donor_loss	1.0000
1:155085405:G:GG	donor_gain	1.0000
1:155085875:A:AG	acceptor_gain	1.0000
1:155085876:G:GG	acceptor_gain	1.0000
1:155085876:GCC:G	acceptor_gain	1.0000
1:155085876:GCCA:G	acceptor_gain	1.0000
1:155085876:GCCAC:G	acceptor_gain	1.0000
1:155085943:G:GG	donor_gain	1.0000
1:155086108:A:AG	acceptor_gain	1.0000
1:155086108:ACCC:A	acceptor_gain	1.0000
1:155086109:C:G	acceptor_gain	1.0000
1:155086111:C:A	acceptor_gain	1.0000
1:155086111:C:CA	acceptor_gain	1.0000
1:155086114:A:AG	acceptor_gain	1.0000
1:155086115:C:G	acceptor_gain	1.0000

AlphaMissense

1540 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:155079050:T:A	W37R	1.000
1:155079050:T:C	W37R	1.000
1:155079052:G:C	W37C	1.000
1:155079052:G:T	W37C	1.000
1:155085132:A:T	D57V	1.000
1:155085138:T:C	L59P	1.000
1:155085149:T:A	C63S	1.000
1:155085149:T:C	C63R	1.000
1:155085150:G:A	C63Y	1.000
1:155085150:G:C	C63S	1.000
1:155085151:C:G	C63W	1.000
1:155085225:T:C	L88P	1.000
1:155085257:T:A	C99S	1.000
1:155085258:G:A	C99Y	1.000
1:155085258:G:C	C99S	1.000
1:155085281:C:A	R107S	1.000
1:155085281:C:G	R107G	1.000
1:155085281:C:T	R107C	1.000
1:155085284:T:A	W108R	1.000
1:155085284:T:C	W108R	1.000
1:155085285:G:C	W108S	1.000
1:155085286:G:C	W108C	1.000
1:155085286:G:T	W108C	1.000
1:155085290:T:A	C110S	1.000
1:155085290:T:C	C110R	1.000
1:155085291:G:A	C110Y	1.000
1:155085291:G:C	C110S	1.000
1:155085291:G:T	C110F	1.000
1:155085292:C:G	C110W	1.000
1:155085326:T:C	F122L	1.000

dbSNP variants (sampled 300 via entrez): RS1000327458 (1:155084986 G>A), RS1000577600 (1:155078256 C>T), RS1000717031 (1:155082925 C>T), RS1000907937 (1:155078667 CAAG>C), RS1001560850 (1:155083216 G>C), RS1001621487 (1:155079392 T>C), RS1001632715 (1:155082926 G>GT), RS1001695220 (1:155079146 G>A), RS1001855059 (1:155084027 G>A,T), RS1001917744 (1:155085629 G>A), RS1001958516 (1:155077648 G>A), RS1002287683 (1:155083667 G>A,C,T), RS1002515799 (1:155087110 G>A,T), RS1002609214 (1:155081753 TG>T), RS1002622754 (1:155080948 G>A,C)

Disease associations

OMIM: gene MIM:601381 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

21 associations (top):

Study	Trait	p-value
GCST001942_19	Prostate cancer	2.000000e-08
GCST004131_70	Inflammatory bowel disease	6.000000e-08
GCST004132_44	Crohn’s disease	2.000000e-07
GCST006586_45	Urinary albumin excretion	7.000000e-09
GCST007294_124	Body fat distribution (trunk fat ratio)	8.000000e-35
GCST007294_3	Body fat distribution (trunk fat ratio)	6.000000e-21
GCST007294_50	Body fat distribution (trunk fat ratio)	1.000000e-15
GCST007295_17	Body fat distribution (leg fat ratio)	3.000000e-13
GCST007295_37	Body fat distribution (leg fat ratio)	7.000000e-17
GCST007295_72	Body fat distribution (leg fat ratio)	1.000000e-28
GCST009462_23	Optic disc size	4.000000e-11
GCST009963_2	Cataracts (operation)	1.000000e-08
GCST010002_367	Refractive error	5.000000e-13
GCST010696_19	Cortical thickness (min-P)	2.000000e-10
GCST010697_10	Cortical surface area (min-P)	3.000000e-10
GCST010698_59	Subcortical volume (min-P)	9.000000e-10
GCST010699_20	Brain morphology (min-P)	7.000000e-10
GCST010700_5	Cortical thickness (MOSTest)	8.000000e-17
GCST010701_66	Cortical surface area (MOSTest)	1.000000e-09
GCST010702_43	Subcortical volume (MOSTest)	3.000000e-10
GCST010703_253	Brain morphology (MOSTest)	4.000000e-14

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004285	albuminuria
EFO:0004341	body fat distribution
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	5
aristolochic acid I	decreases expression	1
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine	increases expression, decreases reaction	1
sotorasib	decreases expression, affects cotreatment	1
kojic acid	decreases expression	1
trichostatin A	affects expression	1
mono-(2-ethylhexyl)phthalate	increases abundance, increases methylation	1
nickel sulfate	affects cotreatment, increases expression	1
pentabromodiphenyl ether	decreases expression	1
CGP 52608	affects binding, increases reaction	1
macrophage stimulatory lipopeptide 2	affects cotreatment, increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
trametinib	decreases expression, affects cotreatment	1
NVP-BKM120	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Leflunomide	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arbutin	decreases expression	1
Arsenic	affects methylation	1
Atrazine	increases expression	1
Azacitidine	increases expression	1
Benzo(a)pyrene	increases methylation	1
Chelating Agents	affects binding, increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Copper	affects binding, increases expression	1
Diethylhexyl Phthalate	increases abundance, increases methylation	1
Lead	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.